Database : MEDLINE
Search on : bisphosphonate-associated and osteonecrosis and of and the and jaw [Words]
References found : 943 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 95 go to page                         

  1 / 943 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28744112
[Au] Autor:Pan WL; Chen PL; Lin CY; Pan YC; Ju YR; Chan CP; Hsu RW
[Ad] Address:Department of Periodontics, Chang Gung Memorial Hospital, Taipei, Taiwan.
[Ti] Title:Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
[So] Source:Clin Interv Aging;12:1089-1093, 2017.
[Is] ISSN:1178-1998
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:Bisphosphonates (BPs) suppress bone resorption and increase bone strength, thus reducing the risk of fracture. Oral BPs are widely used for the prevention and treatment of osteoporosis and osteopenia. Here, we describe the case of a postmenopausal woman who took oral alendronate for >3 years for osteoporosis. The patient presented at the clinic with sharp jaw pain and swelling on the left mandible 4 months after extraction of the third molar. Clinical examinations identified an inflamed mucosal opening with pus over an area of necrotic bone. Initial images of cone beam computed tomography revealed a sequestrum at the extracted socket. The condition did not improve after 1 week of antibiotic treatment; therefore, the alendronate treatment was terminated and the patient was prescribed strontium ranelate instead. The patient gradually recovered and, at the 2-year follow-up, the site of BP-related osteonecrosis of the jaw healed completely as determined by both clinical and cone beam computed tomography measures. The bone mineral densities in the femoral neck and lumbar spine improved after 1 year, and were maintained at the 3-year follow-up. The serum C-terminal cross-linking telopeptide values also gradually increased from the initial 130 pg/mL to 320 pg/mL at the 3-year follow-up. Taken together, this case supports the use of strontium ranelate as an alternative treatment for postmenopausal women who receive long-term oral BP treatments and are at risk for serious complications of BP-related osteonecrosis of the jaw.
[Mh] MeSH terms primary: Alendronate/adverse effects
Bisphosphonate-Associated Osteonecrosis of the Jaw/drug therapy
Bone Density Conservation Agents/adverse effects
Osteoporosis, Postmenopausal/drug therapy
Thiophenes/therapeutic use
[Mh] MeSH terms secundary: Aged, 80 and over
Alendronate/therapeutic use
Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnosis
Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology
Bone Density Conservation Agents/therapeutic use
Diphosphonates/adverse effects
Female
Humans
Postmenopause
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Bone Density Conservation Agents); 0 (Diphosphonates); 0 (Thiophenes); 04NQ160FRU (strontium ranelate); X1J18R4W8P (Alendronate)
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:IM
[Da] Date of entry for processing:170727
[St] Status:MEDLINE
[do] DOI:10.2147/CIA.S141753

  2 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27771152
[Au] Autor:Bagan L; Leopoldo-Rodado M; Poveda-Roda R; Murillo-Cortes J; Diaz-Fernández JM; Bagan J
[Ad] Address:Universidad Europea de Valencia, Valencia, Spain.
[Ti] Title:Grade of sclerosis in the contralateral mandibular area in osteonecrosis of the jaws.
[So] Source:Int J Oral Maxillofac Surg;46(2):167-172, 2017 Feb.
[Is] ISSN:1399-0020
[Cp] Country of publication:Denmark
[La] Language:eng
[Ab] Abstract:The objective of this study was to compare the grade of radiographic sclerosis between the area of osteonecrosis and the at-risk contralateral mandibular area without osteonecrosis. Three groups were studied: group 1 comprised 30 cases of medication-related osteonecrosis of the jaws (MRONJ); group 2 was the healthy contralateral area without osteonecrosis of the group 1 cases; group 3 comprised 30 healthy controls. ImageJ software was used to analyze the computed tomography images, and the grade of bone sclerosis was compared between the three groups. The grade of sclerosis was significantly higher in group 1 than in the other groups (P<0.05); the difference between groups 2 and 3 was not significant. Sclerosis was significantly greater in the area of bone necrosis than in the contralateral mandibular area in patients with MRONJ. No significant differences were found in the grade of sclerosis between the contralateral non-affected mandibular area of patients with MRONJ and the control patients.
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology
Mandibular Diseases/pathology
[Mh] MeSH terms secundary: Aged
Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging
Case-Control Studies
Female
Humans
Male
Mandibular Diseases/diagnostic imaging
Sclerosis
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180209
[Lr] Last revision date:180209
[Js] Journal subset:D; IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  3 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29388023
[Au] Autor:Jung J; Park JS; Righesso L; Pabst AM; Al-Nawas B; Kwon YD; Walter C
[Ad] Address:Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
[Ti] Title:Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
[So] Source:Clin Oral Investig;, 2018 Feb 01.
[Is] ISSN:1436-3771
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To analyze the influence of an oral bisphosphonate and compare the potency to intravenous bisphosphonates on various cell types as regards the rarity of bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) caused by oral bisphosphonate. MATERIALS AND METHODS: A viability assay (MTT), a migration assay (Boyden chamber), and an apoptosis assay (Caspase-Glo® 3/7) were performed to analyze the effect of bisphosphonates on human fibroblasts, umbilical vein endothelial cells (HUVEC), and osteoblasts. RESULTS: Alendronate and intravenous bisphosphonates suppressed cell viability and migration, and induced apoptosis in all tested cell types. Alendronate had a greater impact than ibandronate on the characteristics in fibroblasts and osteoblasts but not as strong as zoledronate. CONCLUSIONS: The incidence of BP-ONJ in oral bisphosphonate treatment is reported to be much lower than that in intravenous bisphosphonates. However, the influences of alendronate on human cells were at least as strong as ibandronate, although it was lower than zoledronate. CLINICAL RELEVANCE: Alendronate showed strong enough effects to suppress human somatic cells and was comparable to certain intravenous bisphosphonates in potency. This study suggests that the lower incidence of BP-ONJ in alendronate treatment is not originated by its potency, but might be due to the low bioavailability of alendronate, lower dosing on a daily basis, and having no additional therapies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180201
[Lr] Last revision date:180201
[St] Status:Publisher
[do] DOI:10.1007/s00784-018-2349-6

  4 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 29236901
[Au] Autor:Oh JS; Kim SG
[Ad] Address:Chosun University, School of Dentistry, Department of Oral and Maxillofacial Surgery, 375, SeoSukDong, DongGu, Gwangju 501-759, Republic of Korea.
[Ti] Title:Collagen sponge and rhBMP-2 improve socket healing in rats treated with zoledronic acid.
[So] Source:Braz Oral Res;31:e99, 2017 Dec 07.
[Is] ISSN:1807-3107
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:The aim of the present study was to evaluate the possible use of a commercial absorbed collagen sponge and bone morphogenetic protein (BMP) for the prevention of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in rats. Twenty rats received intraperitoneal injections of 0.1-mg/kg of zoledronic acid three times a week for eight weeks before the extraction of both maxillary first molars after eight weeks. A collagen sponge (experimental group 1) and a collagen sponge with recombinant human BMP-2 (experimental group 2) were applied to the right extraction sockets of ten rats each. The 20 left extraction sockets (control groups 1 and 2) were left unprotected. After eight weeks, all rats were euthanized. Macroscopic analysis, micro-computed tomography (CT) analysis, and histological analysis were performed. There was a significant difference in the bone density between the control and experimental groups on micro-CT analysis. Impaired healing of the extraction sockets, indicating BRONJ, was observed in 80% of control group 1, 90% of control group 2, 30% of experimental group 1, and 20% of experimental group 2. The collagen sponge with/without BMP used for protecting the extraction socket had the potential for a positive effect in reducing the incidence of bisphosphonate-related osteonecrosis of the jaw in rats.
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control
Bone Morphogenetic Protein 2/administration & dosage
Collagen/administration & dosage
Diphosphonates/pharmacology
Imidazoles/pharmacology
Surgical Sponges
Tooth Socket/drug effects
Transforming Growth Factor beta/administration & dosage
Wound Healing/drug effects
[Mh] MeSH terms secundary: Animals
Female
Rats
Rats, Sprague-Dawley
Recombinant Proteins/administration & dosage
X-Ray Microtomography
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Bone Morphogenetic Protein 2); 0 (Diphosphonates); 0 (Imidazoles); 0 (Recombinant Proteins); 0 (Transforming Growth Factor beta); 0 (recombinant human bone morphogenetic protein-2); 6XC1PAD3KF (zoledronic acid); 9007-34-5 (Collagen)
[Em] Entry month:1801
[Cu] Class update date: 180117
[Lr] Last revision date:180117
[Js] Journal subset:D; IM
[Da] Date of entry for processing:171214
[St] Status:MEDLINE

  5 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29157550
[Au] Autor:Mallya SM; Tetradis S
[Ad] Address:Section of Oral and Maxillofacial Radiology, School of Dentistry, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1668, USA. Electronic address: smallya@ucla.edu.
[Ti] Title:Imaging of Radiation- and Medication-Related Osteonecrosis.
[So] Source:Radiol Clin North Am;56(1):77-89, 2018 Jan.
[Is] ISSN:1557-8275
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Osteonecrosis is the devitalization of bone and consequent lytic changes. In the jaws, osteonecrosis is a pathologic consequence of prior radiation therapy (osteoradionecrosis) or certain antiresorptive medications. Herein, we review the pathogenesis and clinical manifestations of these lesions, and describe the spectrum of radiologic findings in these conditions, and highlight the similarities and differences between the imaging appearances of these 2 entities.
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging
Jaw Diseases/diagnostic imaging
Osteoradionecrosis/diagnostic imaging
Osteoradionecrosis/etiology
Radiation Injuries/diagnostic imaging
Radiography, Dental/methods
[Mh] MeSH terms secundary: Bone Density Conservation Agents/adverse effects
Diagnosis, Differential
Diphosphonates/adverse effects
Humans
Jaw Diseases/etiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Bone Density Conservation Agents); 0 (Diphosphonates)
[Em] Entry month:1711
[Cu] Class update date: 171219
[Lr] Last revision date:171219
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171122
[St] Status:MEDLINE

  6 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28642568
[Au] Autor:Spivakovsky S
[Ad] Address:NYU College of Dentistry, New York, USA.
[Ti] Title:Treatment for bisphosphonate-related osteonecrosis of the jaw.
[So] Source:Evid Based Dent;18(2):56, 2017 06 23.
[Is] ISSN:1476-5446
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Data sourcesCochrane Oral Health Group Trials Register, CENTRAL, Medline, Embase, CancerLit, CINAHL, AMED, clinicaltrials.gov and the WHO International Trial Registry Platform. The reviewers searched six grey literature sites and contacted authors, researchers and pharmaceutical companies.Study selectionRandomised controlled trials for the treatment of BRONJ comparing interventions with other treatment or placebo were included in any setting with no age restriction.Data extraction and synthesisIndependently, two reviewers selected studies for inclusion, risk of bias and data extraction. The main outcome was healing. Secondary outcomes were pain improvement and quality of life.ResultsOne RCT with 49 patients met the inclusion criteria comparing the addition of hyperbaric oxygen therapy to standard of care alone. Changes in the lesion size and number were assessed at 3, 6, 12 and 18 months. Pain was assessed weekly while quality of life was assessed at baseline and six months. Improvement, as measured by the decrease in the size or number of lesions, achieved a RR 1.94, CI 95% (1.01 to 3.74) at three months. No other measure of this outcome was statistically significant. Pain changes and quality of life could not be numerically analysed.ConclusionsThe authors concluded that there is insufficient evidence to support a particular regimen for the treatment of BRONJ.
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw
Quality of Life
[Mh] MeSH terms secundary: Humans
Hyperbaric Oxygenation
[Pt] Publication type:JOURNAL ARTICLE; COMMENT
[Em] Entry month:1710
[Cu] Class update date: 171017
[Lr] Last revision date:171017
[Js] Journal subset:D; IM
[Da] Date of entry for processing:170624
[St] Status:MEDLINE
[do] DOI:10.1038/sj.ebd.6401243

  7 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28414538
[Au] Autor:Critchlow D
[Ad] Address:Senior Dental Officer, Northeast London NHS Foundation Trust, Dental Department, Grays Health Centre.
[Ti] Title:Part 3: Impact of systemic conditions and medications on oral health.
[So] Source:Br J Community Nurs;22(4):181-190, 2017 Apr 02.
[Is] ISSN:1462-4753
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The people who are treated in the community setting will often have multiple comorbidities. Systemic medical conditions can have a negative impact on oral health. In addition, the medications used to treat systemic conditions may also themselves cause oral symptoms. As a large proportion of patients treated by the community nursing team will be elderly, this paper will focus on common geriatric conditions that can display oral or dental symptoms. The effects of medications will be discussed and linked to oral complaints patients may express. The primary aims are to give a broad overview of the oral effects of ageing, of illness and of polypharmacy and advise on how these can be best managed by the nursing team.
[Mh] MeSH terms primary: Aging
Community Health Nursing
Mouth Diseases/nursing
Oral Health
[Mh] MeSH terms secundary: Avitaminosis/complications
Avitaminosis/nursing
Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology
Bisphosphonate-Associated Osteonecrosis of the Jaw/nursing
Dementia/epidemiology
Dementia/nursing
Diabetes Mellitus/epidemiology
Diabetes Mellitus/nursing
Gingival Hyperplasia/epidemiology
Gingival Hyperplasia/nursing
Humans
Malnutrition/complications
Malnutrition/nursing
Mouth Diseases/epidemiology
Mouth Diseases/etiology
Oral Ulcer/epidemiology
Oral Ulcer/etiology
Oral Ulcer/nursing
Parkinson Disease/epidemiology
Parkinson Disease/nursing
Polypharmacy
Risk Factors
Sjogren's Syndrome/complications
Sjogren's Syndrome/nursing
Taste Disorders/epidemiology
Taste Disorders/nursing
Xerostomia/chemically induced
Xerostomia/etiology
Xerostomia/nursing
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1706
[Cu] Class update date: 170615
[Lr] Last revision date:170615
[Js] Journal subset:N
[Da] Date of entry for processing:170418
[St] Status:MEDLINE
[do] DOI:10.12968/bjcn.2017.22.4.181

  8 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28396234
[Au] Autor:Laimer J; Steinmassl O; Hechenberger M; Rasse M; Pikula R; Bruckmoser E
[Ad] Address:Consultant, University Hospital for Craniomaxillofacial and Oral Surgery, Innsbruck, Austria.
[Ti] Title:Intraoral Vacuum-Assisted Closure Therapy-A Pilot Study in Medication-Related Osteonecrosis of the Jaw.
[So] Source:J Oral Maxillofac Surg;75(10):2154-2161, 2017 Oct.
[Is] ISSN:1531-5053
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: For approximately 2 decades, vacuum-assisted closure (VAC) therapy has been widely used for the management of complex wounds and soft tissue defects on the external surface of the body. As yet, this technique has not been studied for intraoral wound management. Therefore, this study evaluated the feasibility, safety, and effectiveness of intraoral VAC therapy in patients with medication-related osteonecrosis of the jaw (MRONJ). PATIENTS AND METHODS: After successful construction of an intraoral device providing sufficient airtight sealing, individually manufactured appliances were used in a prospective clinical trial of 3 patients using the VAC therapy system. RESULTS: Intraoral VAC therapy showed some success and did not produce serious side effects. Different positive effects, such as formation of new granulation tissue, cessation of pain, and pus suppuration, were found. CONCLUSION: This prospective proof-of-principle study showed that intraoral VAC therapy is feasible and safe. It could play a role in the management of MRONJ and other types of intraoral wounds (eg, osteoradionecrosis, postoperative wound dehiscence, etc).
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw/therapy
Negative-Pressure Wound Therapy
[Mh] MeSH terms secundary: Aged
Female
Humans
Male
Middle Aged
Pilot Projects
Prospective Studies
[Pt] Publication type:CASE REPORTS; CLINICAL TRIAL; JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171012
[Lr] Last revision date:171012
[Js] Journal subset:AIM; D; IM
[Da] Date of entry for processing:170412
[St] Status:MEDLINE

  9 / 943 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28359721
[Au] Autor:Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL; Writing Group for the Western Osteoporosis Alliance
[Ad] Address:Departments of Medicine, Oncology, and Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada. Electronic address: dahanley@ucalgary.ca.
[Ti] Title:Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
[So] Source:Am J Med;130(7):862.e1-862.e7, 2017 Jul.
[Is] ISSN:1555-7162
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Osteoporosis is a chronic disease that requires life-long strategies to reduce fracture risk. Few trials have investigated the balance of benefits and risk with long-term use of osteoporosis therapies, and fewer still have investigated the consequences of treatment discontinuation. The best available evidence suggests that up to 10 years of treatment with an oral bisphosphonate maintains the degree of fracture risk reduction observed in the 3-year registration trials. With denosumab, 10 years of therapy appears to provide fracture risk reduction similar to or better than that observed in the 3-year registration trial. Available data suggest an increasing but low risk of fractures with atypical features with increasing duration of bisphosphonate therapy. Published data linking duration of therapy to osteonecrosis of the jaw are lacking for bisphosphonates and denosumab. Other side effects associated with denosumab or bisphosphonates do not appear to be related to therapy duration. The antifracture benefits of long-term therapy with bisphosphonates and denosumab in appropriately selected patients outweigh the low risk of serious side effects.
[Mh] MeSH terms primary: Bone Density Conservation Agents/adverse effects
Bone Density Conservation Agents/therapeutic use
Osteoporosis/drug therapy
[Mh] MeSH terms secundary: Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology
Denosumab/adverse effects
Denosumab/therapeutic use
Diphosphonates/adverse effects
Diphosphonates/therapeutic use
Drug Administration Schedule
Femoral Fractures/chemically induced
Humans
Osteoporotic Fractures/prevention & control
Risk Assessment
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Bone Density Conservation Agents); 0 (Diphosphonates); 4EQZ6YO2HI (Denosumab)
[Em] Entry month:1708
[Cu] Class update date: 170803
[Lr] Last revision date:170803
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170401
[St] Status:MEDLINE

  10 / 943 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28326724
[Au] Autor:Jian P; Qizhang W; Jiyuan L
[Ad] Address:State Key Laboratory of Oral Diseases, Dept. of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
[Ti] Title:[Research progress on bisphosphonate-related osteonecrosis of the jaws].
[So] Source:Hua Xi Kou Qiang Yi Xue Za Zhi;35(1):29-36, 2017 Feb 01.
[Is] ISSN:1000-1182
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:Bisphosphonates (BPs), as potent drugs inhibiting bone resorption, have been widely used for treatment of several diseases. In recent years, dentists and oral and maxillofacial surgeons reported continuously increasing cases of bisphosphonate-related osteonecrosis of the jaws (BRONJ). This disease is clinically characterized by exposed bones, formation of sequestrum, pain, and halitosis. Provided that pathogenesis of BRONJ is unclear, effective treatments for this disease are currently unavailable. Thus, prevention plays an important role in the management of BRONJ. This review summarizes research progress on pathogenesis, risk factors, clinical characteristics, treatment, and prevention of this condition.
[Mh] MeSH terms primary: Bisphosphonate-Associated Osteonecrosis of the Jaw
[Mh] MeSH terms secundary: Bone Density Conservation Agents
Bone Resorption
Diphosphonates
Humans
Jaw
Risk Factors
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Bone Density Conservation Agents); 0 (Diphosphonates)
[Em] Entry month:1704
[Cu] Class update date: 170412
[Lr] Last revision date:170412
[Js] Journal subset:D; IM
[Da] Date of entry for processing:170323
[St] Status:MEDLINE
[do] DOI:10.7518/hxkq.2017.01.004


page 1 of 95 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information